Angelman syndrome drug failure spurs cautious optimism for other therapies

An experimental Angelman syndrome drug failed in a trial, but experts see potential in other similar therapies. The setback highlights the difficulty of treating the genetic disorder, yet the pipeline remains active. The outcome may affect investor sentiment in the rare-disease biotech space.